This includes coordinating with major insurers like UnitedHealthcare, Cigna, Blue Cross Blue Shield, and more
In a 2018 guidance, FDA explained that it would consider a compounded drug to be essentially a copy of a commercially available drug if it has (i) the same API, (ii) the same or similar dosage, and (iii) the same route of administration, unless a prescriber determines that there is a change, made for an identified individual patient, which produces, for that patient, a significant difference from the commercially available drug product. The guidance also explains that, if a change is made for an identified patient, the prescriber should document the determination on the prescription, and the notations should be specific
These dosage guidelines are based on the drugs half-life (i.e
May 2022;8(3):1025-1035
Patients with both obesity and treatment-resistant depression
Retrieved from This post was written by our team of health writers for informational purposes only and does not constitute medical advice